Dexamethasone (DHAP) | CAS#50-02-2 APExBIO貨號A2324

| 代理廠牌: | ![]() |
| 原廠連結: | |
| 相關下載: |
Hypertension Models 系列商品->>Dexamethasone (DHAP)
APExBIO Technology LLC 是一家領先的小分子抑制劑 (Small Molecule Inhibitors)/活化劑(Activators)、化合物庫( Compound Libraries)、胜肽(Peptides)、檢測試劑盒(Assay Kits)、螢光標記(Fluorescent Label)、酶(Enzymes)、修飾核苷酸(Modified Nucleotides)、mRNA 合成以及各種分子生物學工具的供應商。APExBIO提供廣泛的產品線,涵蓋 20 多個不同的研究領域,例如癌症(cancer)、免疫學(immunology)、神經科學(neurosciences)、細胞凋亡(apoptosis)和表觀遺傳學(epigenetics)等。公司總部位於美國德州休士頓USA (Houston, Texas),致力於服務全球客戶。高度重視產品品質。所有產品均遵循嚴格的生產指南,並附有分析證書、HPLC、質譜(Mass Spectrum)和HMNR以及體外驗證(in vitro validation)。 APExBIO產品已被《Nature》、《Cell》和《Science》等眾多頂級同行評審期刊引用。

Dexamethasone (DHAP)| CAS#50-02-2 APExBIO貨號A2324
Glucocorticoidan; anti-inflammatory
Glucocorticoid; anti-inflammatory. Reduces levels of activated NF-κB in immature dendritic cells (DCs) and inhibits differentiation into mature DCs. Induces differentiation of human mesenchymal stem cells (MSCs). Also induces autophagy in acute lymphoblas 糖皮質激素(Glucocorticoid);抗發炎藥(anti-inflammatory)。降低未成熟樹突狀細胞(DC)中活化的NF-κB水平,並抑制其分化為成熟DC。誘導人類骨髓間質幹細胞(MSC)分化。還能誘導急性淋巴球自噬作用。在人類成骨細胞樣細胞株 MG-63 中,地塞米松 (Dex) 呈現劑量依賴性地上調 RhoB 蛋白的表達。 Dex 處理 2 天以上可顯著抑制 MG-63 細胞的生長,且呈現劑量依賴性。在LPS誘導的神經發炎小鼠模型中,鼻內給予DX可顯著降低腦萃取物中IL-6的水平,並在治療後一天降低GFAP+腦細胞的百分比。與靜脈注射相比,鼻內給藥後小鼠腦血管中DX的濃度較高。

| Physical Appearance | A solid |
| Storage | Store at -20°C |
| M.Wt | 392.46 |
| Cas No. | 50-02-2 |
| Formula | C22H29FO5 |
| Solubility | insoluble in H2O; ≥19.623 mg/mL in DMSO; ≥5.18 mg/mL in EtOH |
| Chemical Name | (8R,9R,10S,11S,13S,14S,16R,17R)-9-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-3-one |
| SDF | Download SDF |
| Canonical SMILES | C[C@H](C[C@@H]([C@@H](CCC([C@]1(C)C=C2)=CC2=O)[C@@]11F)[C@]2(C)C[C@@H]1O)[C@@]2(C(CO)=O)O |
| Shipping Condition | Small Molecules with Blue Ice, Modified Nucleotides with Dry Ice. |
| General tips | We do not recommend long-term storage for the solution, please use it up soon. |



| 品項 | CAS# | #貨號 | 應用 |
| Romidepsin (FK228, depsipeptide) |
CAS#128517-07-7
|
貨號A8173 | HDAC1/HDAC2,強效和選擇性抑制劑 |
| Pirarubicin | CAS#72496-41-4 | 貨號B2295 | anthracycline anti-neoplastic doxorubicin |
| Tunicamycin | CAS# 15663-27-1 |
貨號A8321
|
高效、廣譜的化療藥物 |
| Azithromycin | CAS#83905-01-5 | 貨號A2213 | Hsp90 inhibitor |
| Bleomycin Sulfate |
CAS# 9041-93-4
|
貨號B1398 | Antibiotic by inhibiting protein synthesis |
| Nystatin (Fungicidin) | CAS#1400-61-9 | 貨號B1993 | antifungal antibiotic |
| Rapamycin | CAS#53123-88-9 | 貨號A8167 | Original antifungal antibiotic |
| Daptomycin | CAS#103060-53-3 | 貨號A1206 | Calcium-dependent antibiotic |

APExBIO台灣代理商: https://www.apexbt.com/
APExBIO提供優質的胜肽和生物分析試劑,廣泛產品線如Protease、Chromatin/Epigenetics表觀遺傳學、MAPK Signal、DNA Damege/DNA repair、細胞凋亡、腫瘤生物學、Stem cell等研究領域, 還提供定制的服務,包括多肽合成,抗體的生產和檢測的發展。產品線DNA/RNA prep kit、Drug Screening panel、Bioactive peptides、Growth factors、Biotinylation Reagents、tag peptides、amino Acids、Growth factors等。APExBIO產品質量都伴隨著證書的分析,高效液相色譜,質譜,和HMNR數據。

| Cat# | Product Name |
| A8743 | SYBR Safe DNA Gel Stain |
| A6001 | 3X (DYKDDDDK) Peptide |
| K1018 | Cell Counting Kit-8 (CCK-8) |
| A1902 | Z-VAD-FMK |
| A3008 | Y-27632 dihydrochloride |
| A6002 | DYKDDDDK tag Peptide |
| B8362 | 2’3′-cGAMP (sodium salt) |
| F4002 | Phos binding reagent (Phosbind) acrylamide |
| A8011 | Biotin-tyramide |
| A2585 | MG-132 |
| F4005 | Prestained Protein Marker (Triple color, EDTA free, 10-250 kDa) |
| B1274 | AP20187 |
| K1007 | Protease Inhibitor Cocktail(EDTA-Free,100X in DMSO) |
| B8226 | InstaBlue Protein Stain Solution |
| A3011 | CHIR-99021 (CT99021) |
| A3007 | ABT-263 (Navitoclax) |
| B1524 | Erastin |
| B6055 | TCEP hydrochloride |
| K1031 | Phusion high-fidelity DNA polymerase |
| B1387 | (-)-Blebbistatin |
| B4664 | T-5224 |
| A8183 | Trichostatin A (TSA) |
| B3699 | ISRIB (trans-isomer) |
| A1910 | Bromodomain Inhibitor, (+)-JQ1 |
| B1293 | Y-27632 |
| A8167 | Rapamycin (Sirolimus) |
| A7024 | HOAt |
| A7025 | HOBt (anhydrous) |
| A8331 | Bleomycin Sulfate |
| A4333 | CPI-613 |
| K1070 | 2X SYBR Green qPCR Master Mix |
| A8005 | Sulfo-NHS-SS-Biotin |
| B4653 | BV6 |
| B5965 | Tamoxifen |
| A1901 | Q-VD-OPh hydrate |
| A8950 | UM 171 |
| K1046 | RNase Inhibitor, Murine |
| A3317 | Clozapine N-oxide (CNO) |
| A2614 | Bortezomib (PS-341) |
| A8003 | Sulfo-NHS-LC-Biotin |
| A4154 | Olaparib (AZD2281, Ku-0059436) |
| A8012 | Biotin-XX Tyramide Reagent |
| K1101 | PreScission Protease (PSP) |
| A8627 | Bafilomycin A1 |
| A8001 | Sulfo-NHS-Biotin |
| A3017 | Dasatinib (BMS-354825) |
| A2576 | E-64 |
| K1051 | Cy3 TSA Fluorescence System Kit |
| K1034 | 2X Taq PCR Master Mix (with dye) |
| B7972 | Pseudo-UTP |
| A8173 | Romidepsin (FK228, depsipeptide) |
| A4219 | Birinapant (TL32711) |
| A4371 | Ferrostatin-1 (Fer-1) |
| A8200 | DAPT (GSI-IX) |
| A8249 | SB 431542 |
| K1008 | Protease Inhibitor Cocktail (EDTA-Free, 200X in DMSO) |
| A3133 | A 83-01 |
| A8192 | Staurosporine |
| B1054 | Resiquimod (R-848) |
| A3018 | Trametinib (GSK1120212) |
| A8184 | AICAR |
| K1025 | Direct Mouse Genotyping Kit |
| A2606 | Epoxomicin |
| A6006 | Hexa His tag peptide |
| A4393 | Paclitaxel (Taxol) |
| A8315 | NU7441 (KU-57788) |
| A4213 | Necrostatin-1 |
| A8885 | Ro 3306 |
| L1021 | DiscoveryProbe™ FDA-approved Drug Library |
| B1464 | KPT-330 |
| A8815 | SM-164 |
| B4879 | Blasticidin S HCl |
| A8793 | N3-kethoxal |
| K1047 | HyperScribe™ T7 High Yield RNA Synthesis Kit |
| A6004 | Influenza Hemagglutinin (HA) Peptide |
| B1036 | MLN4924 |
| A8178 | Panobinostat (LBH589) |
| A3963 | A-769662 |
| A3847 | SU5416 |
| B3252 | Dorsomorphin (Compound C) |
| B4758 | BAPTA-AM |
| A2513 | Geneticin, G-418 Sulfate |
| B6004 | PX-478 2HCl |
| A8955 | Z-YVAD-FMK |
| A8193 | ABT-737 |
| B2083 | Caspofungin Acetate |
| A8002 | NHS-Biotin |
| A8337 | CX-5461 |
| A8312 | Torin 1 |
| A2570 | Leupeptin, Microbial |
| K2170 | Alanine Aminotransferase (ALT or SGPT) Activity Colorimetric/Fluorometric Assay Kit |
| A4381 | FK866 (APO866) |
| B2143 | Tacrolimus (FK506) |
| A2571 | Pepstatin A |
| k1072 | First-Strand cDNA Synthesis Kit |
| A3003 | MDV3100 (Enzalutamide) |
| B5997 | Dyngo-4a |
| A3742 | Pyridostatin |
APExBIO台灣代理商
APExBIO提供優質的胜肽和生物分析試劑,廣泛產品線如Protease、Chromatin/Epigenetics表觀遺傳學、MAPK Signal、DNA Damege/DNA repair、細胞凋亡、腫瘤生物學、Stem cell等研究領域, 還提供定制的服務,包括多肽合成,抗體的生產和檢測的發展。產品線DNA/RNA prep kit、Drug Screening panel、Bioactive peptides、Growth factors、Biotinylation Reagents、tag peptides、amino Acids、Growth factors等。APExBIO產品質量都伴隨著證書的分析,高效液相色譜,質譜,和HMNR數據。
| 品項 | CAS# | #貨號 | 應用 |
| Romidepsin (FK228, depsipeptide) |
CAS#128517-07-7
|
貨號A8173 | HDAC1/HDAC2,強效和選擇性抑制劑 |
| Pirarubicin | CAS#72496-41-4 | 貨號B2295 | anthracycline anti-neoplastic doxorubicin |
| Tunicamycin | CAS# 15663-27-1 |
貨號A8321
|
高效、廣譜的化療藥物 |
| Azithromycin | CAS#83905-01-5 | 貨號A2213 | Hsp90 inhibitor |
| Bleomycin Sulfate |
CAS# 9041-93-4
|
貨號B1398 | Antibiotic by inhibiting protein synthesis |
| Nystatin (Fungicidin) | CAS#1400-61-9 | 貨號B1993 | antifungal antibiotic |
| Rapamycin | CAS#53123-88-9 | 貨號A8167 | Original antifungal antibiotic |
| Daptomycin | CAS#103060-53-3 | 貨號A1206 | Calcium-dependent antibiotic |
| Catalog No. | Name | CAS | Purity | Short Summary |
| A1001 | Adrenomedullin (1-12), human | 98.99% | Vasodilator | |
| A1002 | Beta-Amyloid (1-11) | 190436-05-6 | 98.58% | Amyloidogenic peptide |
| A1003 | Amyloid β-Protein (1-15) | 183745-81-5 | 98.58% | Principal component of amyloid |
| A1004 | Amyloid Precursor C-Terminal Peptide | 92.28% | For beta amyloid generation | |
| A1005 | Beta-Sheet Breaker Peptide iAβ5 | 182912-74-9 | 98.17% | Peptide which can inhibit amyloidogenesis |
| A1006 | Angiotensin I (human, mouse, rat) | 484-42-4 | 98.99% | Precursor of angiotensin II |
| A1007 | Angiotensin 1/2 (1-9) | 34273-12-6 | 98.77% | Vasoconstrictor |
| A1008 | Anti-Inflammatory Peptide 1 | 118850-71-8 | 99.99% | PLA2 inhibitor |
| A1009 | ANP (1-11), rat | 95.92% | Vasodilator | |
| A1010 | Myelopeptide-2 (MP-2) | 98.98% | Peptide used for restoring human T lymphocytes | |
| A1011 | b-Casomorphin (1-3) | 72122-59-9 | 99.56% | Milk protein casein analog, have an opioid effect |
| A1012 | Dynorphin (2-17), amide, porcine | 99.94% | A modulator of pain response | |
| A1013 | Endomorphin-1 | 189388-22-5 | 98.79% | Agonist of μopioid receptors,highly potent and selective |
| A1014 | Beta-Lipotropin (1-10), porcine | 77875-68-4 | 99.17% | Morphine-like substance |
| A1015 | alpha-Endorphin | 59004-96-5 | 98.00% | Neurotransmitters |
| A1016 | Ac-Endothelin-1 (16-21), human | 98.49% | ETA/ETB agonist,vasoconstrictor | |
| A1018 | Platelet Membrane Glycoprotein IIB Peptide (296-306) | 98.92% | Inhibits platelet aggregation | |
| A1019 | Glucagon (19-29), human | 64790-15-4 | 95.54% | Potent Ca2+/Mg2+-ATPase inhibitor |
| A1020 | GnRH Associated Peptide (GAP) (1-13), human | 100111-07-7 | 99.41% | Inhibitor of prolactin secretion |
| A1021 | Epidermal Growth Factor Receptor Peptide (985-996) | 96249-43-3 | 98.41% | EGFR Peptide (985-996) |
| A1022 | GTP-Binding Protein Fragment, G alpha | 74.64% | Hydrolyzes GTP to GDP | |
| A1023 | Laminin (925-933) | 110590-60-8 | 99.93% | Extracellular matrix glycoprotein |
| A1024 | LEP (116-130) (mouse) | 258276-95-8 | 98.17% | An antiobesity hormone |
| A1025 | a-MSH, amide | 581-05-5 | 99.59% | Melanocyte-stimulating hormones |
| A1026 | β-Interleukin I (163-171), human | 106021-96-9 | 99.58% | T cell activator |
| A1027 | β-Interleukin II (44-56) | 99.37% | Cytokine,regulating WBC | |
| A1028 | Cadherin Peptide, avian | 127650-08-2 | 99.90% | Role in cell adhesion |
| A1029 | Fas C- Terminal Tripeptide | 189109-90-8 | 97.61% | AC-SER-LEU-VAL-OH |
| A1030 | Interleukin II (60-70) | 99.99% | Cytokine,regulating WBC | |
| A1031 | Myelin Basic Protein (68-82), guinea pig | 98474-59-0 | 99.06% | Myelin Basic Protein |
| A1032 | Adrenorphin | 88377-68-8 | 97.00% | Endogenous μ/κ opioid agonist,potent and selective |
| A1033 | [Ser25] Protein Kinase C (19-31) | 136795-05-6 | 99.80% | PKC substrate |
| A1034 | Acetyl Angiotensinogen (1-14), porcine | 66641-26-7 | 99.81% | Angiotensinogen precursor |
| A1035 | Papain Inhibitor | 70195-20-9 | 97.15% | Inhibitor of peptidase activity of Papain |
| A1036 | Thrombin Receptor Activator for Peptide 5 (TRAP-5) | 141685-53-2 | 98.07% | Thrombin Receptor Activator for Peptide 5 |
| A1037 | TRH Precursor Peptide | 98.91% | Thyrotropin Releasing Hormone Precursor Peptide | |
| A1040 | Myelin Basic Protein (87-99) | 118506-26-6 | 99.85% | Encephalitogenic peptide |
| A1041 | Angiotensin (1-7) | 51833-78-4 | 99.70% | Vasoconstriction peptide hormone |
| A1043 | Angiotensin III (human, mouse) | 13602-53-4 | 98.97% | Aldosterone stimulator |
| A1044 | Gap 26 | 197250-15-0 | 99.56% | Gap junction blocker peptide, mapping to connexin 43 residue 63-75 |
| A1045 | Gap 27 | 198284-64-9 | 97.64% | Selective gap junction blocker |
| A1046 | Dynamin inhibitory peptide | 251634-21-6 | 99.53% | Peptide inhibitor of GTPase dynamin |
| A1047 | Angiotensin 1/2 (1-5) | 58442-64-1 | 99.65% | Vasoconstrictor |
| A1048 | Angiotensin 1/2 (1-6) | 47896-63-9 | 99.85% | Vasoconstrictor |
| A1049 | Angiotensin 1/2 (5-7) | 98.36% | Vasoconstrictor | |
| A1050 | Angiotensin 1/2 (2-7) | 99.80% | Vasoconstrictor | |
| A1051 | alpha-1 antitrypsin fragment | 99.10% | Protease inhibitor | |
| A1052 | alpha-1 antitrypsin fragment 235-243 [Homo sapiens]/[Papio hamadryas]/[Cercopithecus aethiops] | 98.00% | Protease inhibitor | |
| A1053 | amyloid A protein fragment [Homo sapiens] | 99.77% | Apolipoproteins related to HDL in plasma | |
| A1056 | Angiotensin 1/2 + A (2 – 8) | 51833-76-2 | 99.56% | Vasoconstrictor |
| A1057 | coagulation factor II (thrombin) B chain fragment [Homo sapiens] | 99.68% | Trypsin-like serine protease | |
| A1058 | Prothrombin (474-477) [Mus musculus] | 99.61% | Role in coagulation cascade | |
| A1061 | Cytochrome c – pigeon (88-104) | 86579-06-8 | 98.58% | Triggers T Cell response |
| A1062 | Cytochrome c fragment (93-108) | 99.20% | Initiates apoptosis | |
| A1063 | Cytochrome P450 CYP1B1 (190-198) [Homo sapiens] | 98.32% | Sequence: H2N-FLDPRPLTV-OH | |
| A1066 | erbB-2 | 99.72% | Tyrosine kinase (TK) receptor | |
| A1067 | eukaryotic translation elongation factor 1 alpha 1 (EEF1A1) (387-394) [Multiple species] | 98.20% | Elongation factor-1 subunit | |
| A1068 | eukaryotic translation initiation factor 3 | 98.44% | Eukaryotic translation initiator | |
| A1069 | ferritin heavy chain fragment [Multiple species] | 99.67% | Ferritin heavy chain fragment | |
| A1070 | IgG light chain variable region [Homo sapiens]/IgM/kappa antibody [Mus musculus] | 99.79% | IgG light chain region | |
| A1071 | immunoglobulin light chain variable region fragment [Homo sapiens] | 99.82% | Immunoglobulin light chain fragment | |
| A1072 | immunoglobulin light chain variable region fragment [Homo sapiens]/[Mus musculus] | 97.50% | Immunoglobulin light chain fragment | |
| A1073 | Immunoglobulin M heavy chain (IGHM) fragment [Homo sapiens] | 99.36% | Immunoglobulin M heavy chain | |
| A1075 | Influenza A virus fragment | 97.61% | Leu-Lys-Phe-Ala-Phe-Ser-Met-Met | |
| A1077 | Lamin fragment | 99.57% | Lys-Ala-Gly-Gln-Val-Val-Thr-Ile-Trp | |
| A1078 | Large T antigen – rhesus polyomavirus 560-568 | 99.08% | Large T antigen | |
| A1079 | MAP kinase fragment [Multiple species] | 97.00% | Lys-Tyr-Ile-His-Ser-Ala-Asn-Val-Leu | |
| A1080 | matrix protein (3-15) [Zaire ebolavirus] | 98.14% | Viral envelope associated protein peptide | |
| A1081 | MHC class II antigen (45-57) [Homo sapiens] | 83.75% | Major histocompatibility complex | |
| A1082 | ovalbumin (324-338) [Gallus gallus]/[Coturnix coturnix] | 98.23% | Triggers immuno response | |
| A1083 | p53 tumor suppressor fragment | 99.00% | Regulates cell cycle | |
| A1084 | parathyroid hormone (7-34) [Homo sapiens]/[Macaca fascicularis] | 99.71% | Enhancer of blood calcium level | |
| A1085 | prostate apoptosis response protein PAR-4 (2-7) [Homo sapiens] | 99.46% | Transcriptional repressor | |
| A1086 | Rac GTPase fragment | 99.65% | Fragment of small signaling G proteins | |
| A1087 | Rhodopsin peptide | 99.88% | Pigment in retina photoreceptor cell;GPCR | |
| A1088 | Ribosomal protein L3 peptide (202-222) amide | 99.76% | HIV-1 TAR RNA-binding protein | |
| A1090 | signal transducer and activator of transcription 6 fragment | 99.79% | STAT6 transcription factor | |
| A1092 | survivin (baculoviral IAP repeat-containing protein 5) (21-28) | 98.07% | Cancer Biology Peptides | |
| A1093 | transferrin fragment | 99.69% | Transferrin fragment | |
| A1094 | tumor protein p53 binding protein fragment [Homo sapiens]/[Mus musculus] | 99.06% | P53 binding protein fragment | |
| A1096 | type II collagen fragment | 99.56% | Specific for cartilaginous tissues | |
| A1097 | ubiquitin specific protease 3 fragment | 96.99% | Deubiquitinates uH2A/uH2B | |
| A1098 | vitamin D binding protein precrusor (208-218) [Homo sapiens]/[Oryctolagus cuniculus] | 99.83% | vitamin D binding protein precrusor | |
| A1099 | vitamin D binding protein precursor (353-363) [Homo sapiens] | 99.52% | Highly polymorphic serum glycoprotein | |
| A1105 | BNP (1-32), human | 114471-18-0 | 98.00% | Brain natriuretic peptide |
| A1107 | Cdk2/Cyclin Inhibitory Peptide I | 99.88% | Cell division protein kinase 2 | |
| A1109 | Endostatin (84-114)-NH2 (JKC367) | 99.66% | Angiogenesis inhibitor | |
| A1111 | Endothelin-1 (1-15), amide, human | 98.00% | Vasoconstrictor agent | |
| A1112 | Nitric Oxide Synthase (599-613) Blocking Peptide, Bovine Endothelial Cell | 99.74% | Blocker of NO production | |
| A1114 | Parathyroid Hormone (1-34), bovine | 12583-68-5 | 99.84% | Enhancer of blood calcium level |
| A1115 | Peptide YY(3-36), PYY, human | 123583-37-9 | 96.92% | Y2R agonist |
| A1117 | PKA inhibitor fragment (6-22) amide | 121932-06-7 | 98.62% | PKA inhibitor |
| A1118 | S6 Kinase Substrate Peptide 32 | 98.28% | Measures the activity of kinases that phosphorylate ribosomal protein S6. | |
| A1121 | Melanocyte stimulating hormone release inhibiting factor | 2002-44-0 | 98.00% | MSH release-inhibiting factor |
| A1123 | Amyloid Beta-Peptide (12-28) (human) | 107015-83-8 | 99.46% | sequence H2N-VHHQKLVFFAEDVGSNK-OH |
| A1124 | Amyloid Beta-Peptide (1-40) (human) | 131438-79-4 | 98.43% | Amyloid precursor protein |
| A1129 | Parathyroid hormone (1-34) (human) | 52232-67-4 | 99.82% | Increases blood calcium level |
| A1131 | COG 133 | 514200-66-9 | 99.03% | ApoE mimetic peptide |
| A1132 | β-Pompilidotoxin | 216064-36-7 | 99.84% | Slows Na+ channel inactivation |
| A1133 | Epidermal growth factor receptor (994-1002) acetyl/amide | 98.50% | EGF-family receptor | |
| A1134 | Agouti-related Protein (AGRP) (25-82), human | 99.67% | Agouti-related peptide(25-82) | |
| A1136 | Fusion glycoprotein (92-106) [Human respiratory syncytial virus] | 98.42% | glycoprotein | |
| A1138 | Glycoprotein B (485-492) | 99.61% | Invovled in HSV viral cell entry | |
| A1140 | HBcAg [Hepatitis B virus] (18-27) | 99.74% | Indicator of active viral replication | |
| A1141 | hemagglutinin (332-340) [Influenza A virus] | 98.84% | Partial antigenic glycoprotein | |
| A1142 | hemagglutinin precursor (114-122) amide [Influenza A virus] | 99.70% | Partial antigenic glycoprotein | |
| A1143 | heparin cofactor II precursor (SERPIND1) fragment [Homo sapiens] | 98.14% | Thrombin inhibitor | |
| A1144 | heparin cofactor II precursor fragment [Homo sapiens] | 99.72% | Thrombin inhibitor | |
| A1146 | Histone-H2A-(107-122)-Ac-OH | 97.81% | Histone-H2A peptide | |
| A1147 | Luteinizing hormone releasing hormone human acetate salt (LHRH) | 33515-09-2 | 98.34% | acitivator of MMP-2 and MMP-9, selective |
| A1149 | YAP-TEAD Inhibitor 1 (Peptide 17) | 99.56% | ||
| A1169 | 10058-F4 | 403811-55-2 | 98.03% | C-Myc-Max dimerization inhibitor |
| A1173 | AG-18 | 118409-57-7 | 99.68% | EGFR/PDGFR inhibitor |
| A1174 | AMG-517 | 659730-32-2 | 96.97% | TRPV1 antagonist,potent and highly selective |
| A1185 | BMS-754807 | 1001350-96-4 | 99.53% | IGF-1R/InsR inhibitor,potent and selective |
| A1186 | AMG-208 | 1002304-34-8 | 98.00% | C-Met inhibitor,potent and highly selective |
| A1196 | SGX-523 | 1022150-57-7 | 99.73% | MET inibitor, highly selective, ATP-competitive |
| A1198 | Levetiracetam | 102767-28-2 | 98.00% | Antiepileptic drug |
| A1206 | Daptomycin | 103060-53-3 | 98.77% | Calcium-dependent antibiotic |
| A1229 | Lansoprazole | 103577-45-3 | 98.00% | H+,K+-ATPase inhibitor |
| A1266 | WYE-354 | 1062169-56-5 | 99.39% | MTOR inhibitor,potent,ATP-competitive and cell-permeable |
| A1267 | Adapalene | 106685-40-9 | 99.91% | RARβ and RARγ agonist |
| A1295 | Granisetron HCl | 107007-99-8 | 99.85% | 5-HT3 receptor antagonist |
| A1296 | Exemestane | 107868-30-4 | 98.00% | Steroidal aromatase inhibitor,selective and irreversible |
| A1302 | GSK1904529A | 1089283-49-7 | 98.55% | Selective IGF-1R/IR inhibitor |
| A1307 | Letrozole | 112809-51-5 | 99.90% | Non-steroidal aromatase inhibitor |
| A1313 | Gatifloxacin | 112811-59-3 | 99.70% | Fluoroquinolone antibiotic,inhibits bacterial TOPO II |
| A1334 | Mosapride Citrate | 112885-42-4 | 99.90% | 5-HT receptor agonist |
| A1337 | U0126-EtOH | 1173097-76-1 | 99.34% | MEK1/2 inhibitor |
| A1352 | Zoledronic Acid | 118072-93-8 | 98.00% | Potent nitrogen-containing bisphosphonates |
| A1366 | Rocuronium Bromide | 119302-91-9 | 98.00% | TGF-βR I kinase inhibitor |
| A1367 | AP26113 | 1197958-12-5 | 98.00% | Anaplastic lymphoma kinase (ALK) inhibitor |
| A1372 | AZD3514 | 1240299-33-5 | 98.00% | Androgen receptor downregulator |
| A1373 | Biapenem | 120410-24-4 | 98.00% | Highly broad spectrum antibiotic agent |
| A1379 | Nelarabine | 121032-29-9 | 98.44% | Prodrug of ara-G for T-LBL/T-ALL |
| A1379 | Nelarabine | 121032-29-9 | 98.44% | Prodrug of ara-G for T-LBL/T-ALL |
| A1379 | Nelarabine | 121032-29-9 | 98.44% | Prodrug of ara-G for T-LBL/T-ALL |
| A1379 | Nelarabine | 121032-29-9 | 98.44% | Prodrug of ara-G for T-LBL/T-ALL |
| A1387 | AZD5363 | 1143532-39-1 | 99.94% | AKT inhibitor,pyrrolopyrimidine derived |
| A1389 | WZ4002 | 1213269-23-8 | 98.89% | Mutant-selective EGFR inhibitor(L858R,T790M), irreversible and potent |
| A1393 | WZ8040 | 1214265-57-2 | 98.36% | EGFR T790M inhibitor,irreversible amd potent |
| A1402 | Gemcitabine HCl | 122111-03-9 | 99.92% | Inhibits DNA synthesis,deoxycytidine analog |
| A1404 | Rigosertib sodium salt | 1225497-78-8 | 98.79% | Plk1 inhibitor |
| A1412 | Clofarabine | 123318-82-1 | 99.41% | Antimetabolite,inhibit DNA polymerase and ribonucleotide reductase |
| A1413 | CEP-32496 | 1188910-76-0 | 98.27% | BRAF(V600E)inhibitor,highly potent |
| A1425 | Losartan Potassium (DuP 753) | 124750-99-8 | 99.87% | Angiotensin AT1 receptor antagonist |
| A1428 | Fulvestrant (ICI 182,780) | 129453-61-8 | 99.18% | Estrogen receptor antagonist, high affinity |
| A1435 | CP-945598 HCl | 686347-12-6 | 98.00% | CB1 antagonist,selective and high affinity |
| A1447 | Cilnidipine | 132203-70-4 | 99.94% | Blocker of Dual L- and N-type calcium channel |
| A1450 | Lidocaine | 137-58-6 | 99.92% | Anasthetic and class Ib antiarrhythmic agent |
| A1493 | ABT-751 (E7010) | 141430-65-1 | 99.38% | Inhibitor of microtubule polymerization,antimitotic |
| A1500 | 7-Methoxycoumarin-4-acetyl-P-L-G-L-β-(2,4-dinitrophenylamino)A-R amide | 140430-53-1 | 99.93% | Substrate of matrix metalloproteinases assay |
| A1501 | Mca-Pro-Leu-NH2 | 98.00% | Substrate of matrix metalloproteinases assay | |
| A1602 | Dexrazoxane HCl (ICRF-187, ADR-529) | 149003-01-0 | 99.85% | Topoisomerase II inhibitor,intracellular ion chelator,cardioprotective agent |
| A1605 | Dynasore | 304448-55-3 | 98.00% | Dynamin and GTPase inhibitor |
| A1606 | L-a-Hydroxyglutaric acid disodium salt | 63512-50-5 | 95.00% | salt form of L-α-Hydroxyglutaric acid |
| A1615 | GANT61 | 500579-04-4 | 99.50% | GLI antagonist |
| A1623 | Epothilone A | 152044-53-6 | 98.00% | Microtubule stabilizing macrolide |
| A1624 | Zaragozic Acid A | 142561-96-4 | 98.00% | rat liver squalene synthase inhibitor |
| A1630 | Epothilone B (EPO906, Patupilone) | 152044-54-7 | 99.72% | Microtubule stabilizing macrolide |
| A1632 | SB202190 (FHPI) | 152121-30-7 | 99.84% | P38 MAPK inhibitor |
| A1655 | GW2580 | 870483-87-7 | 99.69% | CFMS kinase/CSF-1R inhibitor,selective and ATP-competitive |
| A1659 | Dutasteride | 164656-23-9 | 99.46% | 5-alpha-reductase inhibitor |
| A1663 | PD98059 | 167869-21-8 | 99.25% | MEK inhibitor,selective and reversible |
| A1664 | Celecoxib | 169590-42-5 | 99.71% | Selective cyclooxygenase-2 (COX-2) inhibitor |
| A1670 | Enzastaurin (LY317615) | 170364-57-5 | 98.94% | PKC beta inhibitor,potent and selective |
| A1684 | Aprepitant | 170729-80-3 | 98.62% | Substance P (SP) inhibitor |
| A1709 | GW9508 | 885101-89-3 | 99.93% | FFA1/GPR40 agonist,potent and selective |
| A1718 | Posaconazole | 171228-49-2 | 99.47% | Sterol C14ɑ demethylase inhibitor |
| A1720 | Duvelisib (IPI-145, INK1197) | 1201438-56-3 | 99.55% | PI3K-δ/PI3K-γ inhibitor |
| A1723 | Roscovitine (Seliciclib,CYC202) | 186692-46-6 | 99.10% | CDK inhibitor,potent and selective |
| A1736 | PA-824 | 187235-37-6 | 99.62% | Anti-tuberculosis drug |
| A1745 | Galanthamine HBr | 1953-04-4 | 98.81% | Acetylcholinesterase inhibitor |
| A1748 | Ramelteon | 196597-26-9 | 99.89% | Agonist of melatonin receptor(M1-M2),highly selective |
| A1755 | Tenofovir Disoproxil Fumarate | 202138-50-9 | 98.61% | Antiretroviral agent( HIV-1 RT inhibitor) |
| A1765 | Vincristine sulfate | 2068-78-2 | 98.64% | Microtubule disrupter,antitumor agent |
| A1767 | Entecavir Hydrate | 209216-23-9 | 99.67% | Antiviral drug used in hepatitis B infection |
| A1769 | KU-0060648 | 881375-00-4 | 98.00% | Dual DNA-PK/PI3-K inhibitor, ATP-competitive |
| A1778 | Vatalanib (PTK787) 2HCl | 212141-51-0 | 99.95% | Tyrosine kinase receptor inhibitor |
| A1792 | PD184352 (CI-1040) | 212631-79-3 | 99.41% | Selective MEK inhibitor |
| A1794 | LY2835219 | 1231930-82-7 | 98.48% | CDK4/6 inhibitor,potent and selective |
| A1796 | Mianserin HCl | 21535-47-7 | 99.42% | 5-HT2 receptor antagonist |
| A1821 | Ki8751 | 228559-41-9 | 99.43% | VEGFR-2 inhibitor,potent and selective |
| A1832 | Doxorubicin (Adriamycin) HCl | 25316-40-9 | 99.64% | Antitumour antibiotic,inhibits TOPO II. |
| A1835 | Pelitinib (EKB-569) | 257933-82-7 | 98.49% | EGFR inhibitor,potent and irreversible |
| A1845 | Canertinib (CI-1033) | 267243-28-7 | 99.52% | HER family tyrosine kinase inhibitor |
| A1855 | Bumetanide | 28395-03-1 | 98.77% | NKCC cotransporter inhibitor |
| A1882 | Cediranib (AZD217) | 288383-20-0 | 99.82% | VEGFR inhibitor receptor,highly potent |
| A1888 | TRAM-34 | 289905-88-0 | 98.00% | KCa3.1 blocker,potent and highly selective |
| A1894 | SL-327 | 305350-87-2 | 99.80% | Selective MEK1/2 inhibitor |
| A1900 | PSI | 158442-41-2 | 97.64% | Proteasome inhibitor |
| A1901 | Q-VD-OPh hydrate | 1135695-98-5 | 98.32% | Cell-permeable, irreversible pan-caspase inhibitor |
| A1902 | Z-VAD-FMK | 187389-52-2 | 98.60% | Cell-permeable, irreversible pan-caspase inhibitor |
| A1903 | E 64d | 88321-09-9 | 98.14% | Cysteine protease inhibitor |
| A1904 | Boc-D-FMK | 187389-53-3,634911-80-1 | 98.00% | Pan-caspase inhibitor |
| A1905 | 3-Deazaneplanocin,DZNep | 102052-95-9 | 98.00% | S-adenosylhomocysteine and EZH2 inhibitor |
| A1906 | Decitabine (NSC127716, 5AZA-CdR) | 2353-33-5 | 99.77% | Deoxycytidine analog and cellular diifferentiation inducer |
| A1907 | 5-Azacytidine | 320-67-2 | 98.00% | DNA methyltransferase inhibitor. |
| A1908 | AMI-1 | 20324-87-2 | 99.49% | PRMT1 inhibitor |
| A1909 | BIX 01294 | 935693-62-2 | 98.38% | G9a and GLP inhibitor |
| A1910 | Bromodomain Inhibitor, (+)-JQ1 | 1268524-70-4 | 98.98% | BET bromodomain inhibitor |
| A1912 | Lomeguatrib | 192441-08-0 | 99.55% | MGMT inhibitor |
| A1913 | RG 108 | 48208-26-0 | 99.86% | DNA methyltransferase inhibitor |
| A1914 | UNC0638 | 1255580-76-7 | 98.66% | G9a/GLP HMTase inhibitor, potent and selective |
| A1915 | Zebularine | 3690-10-6 | 99.18% | DNA methylation inhibitor |
| A1920 | Z-DEVD-FMK | 210344-95-9 | 98.00% | Caspase-3 inhibitor |
| A1921 | Z-DQMD-FMK | 767287-99-0 | 98.00% | Caspase-3 inhibitor,cell-permeable |
| A1922 | Z-VDVAD-FMK | 210344-92-6 | 98.00% | Caspase-2 inhibitor |
| A1923 | Z-VEID-FMK | 98.41% | Caspase-6 inhibitor | |
| A1924 | Z-WEHD-FMK | 210345-00-9 | 98.00% | Caspase 5 inhibitor,potent,cell-permeable and irreversible |
| A1925 | Caspase-3/7 Inhibitor I | 220509-74-0 | 99.31% | Caspase-3/7 inhibitor |
| A1926 | CA 074 | 134448-10-5 | 98.07% | Cathepsin B inhibitor |
| A1930 | Apoptosis Inhibitor | 54135-60-3 | 99.70% | Associate with caspase-3 inhibition |
| A1931 | Pyronaridine Tetraphosphate | 76748-86-2 | 99.47% | Antimalarial agent |
| A1932 | (-)-Huperzine A | 102518-79-6 | 99.63% | NMDA receptor antagonist/AChE inhibitor |
| A1933 | Carfilzomib (PR-171) | 868540-17-4 | 99.76% | Proteasome inhibitor, epoxomicin analog |
| A1934 | Oprozomib (ONX-0912) | 935888-69-0 | 97.63% | Proteasome inhibitor |
| A1935 | 5-Aminovaleric acid hydrochloride | 660-88-8 | 98.00% | used for the synthesis of polymers |
| A1945 | BIBR 1532 | 321674-73-1 | 99.80% | Telomerase inhibitor,novel and selective |
| A1947 | MEK162 (ARRY-162, ARRY-438162) | 606143-89-9 | 98.17% | MEK1/2 inhibitor,potent and selective |
| A1952 | NSC 23766 | 1177865-17-6 | 98.21% | Selective inhibitor of Rac1-GEF interaction. |
| A1958 | Etomidate | 33125-97-2 | 99.84% | General anesthetic with GABA modulatory and GABA-mimetic actions |
| A1971 | Etoposide | 33419-42-0 | 99.56% | Topo II inhibitor |
| A1980 | SNS-032 (BMS-387032) | 345627-80-7 | 99.49% | CDK inhibitor |
| A1984 | Bendamustine HCl | 3543-75-7 | 99.74% | Cytostatic agent for non-Hodgkin lymphomas |
| A1986 | Nu 6027 | 220036-08-8 | 98.00% | ATR/CDK inhibitor, potent and selective |
| A1987 | Ki16425 | 355025-24-0 | 99.02% | LPA receptor antagonist |
| A2005 | Nutlin-3b | 675576-97-3 | 98.48% | MDM2/p53 inhibitor |
| A2024 | PD168393 | 194423-15-9 | 98.00% | EGFR inhibitor |
| A2025 | Plerixafor (AMD3100) | 110078-46-1 | 98.00% | CXCR4 chemokine receptor antagonist |
| A2033 | PQ 401 | 196868-63-0 | 98.00% | IGF1R inhibitor,potent and cell-permeable |
| A2036 | Doripenem Hydrate | 364622-82-2 | 99.43% | Injectable antibiotic,ultra-broad spectrum |
| A2065 | IC-87114 | 371242-69-2 | 98.00% | PI3Kδ inhibitor |
| A2067 | PI-103 | 371935-74-9 | 98.66% | Class I PI3K, mTOR and DNA-PK inhibitor |
| A2080 | PIK-75 | 372196-77-5 | 99.40% | Inhibitor of PI3K isoform p110α |
| A2097 | Ifosfamide | 3778-73-2 | 98.65% | Cytostatic agent |
| A2098 | PRX-08066 Maleic acid | 866206-55-5 | 98.00% | 5-HT2B receptor antagonist,potent and selective |
| A2133 | Saracatinib (AZD0530) | 379231-04-6 | 99.86% | Src/Abl inhibitor,potent and selective |
| A2149 | Bosutinib (SKI-606) | 380843-75-4 | 99.78% | Potent Abl/Src kinases |
| A2150 | Andarine | 401900-40-1 | 99.78% | Androgen receptor agonist |
| A2168 | Dovitinib (TKI-258, CHIR-258) | 405169-16-6 | 99.81% | Multitargeted RTK inhibitor |
| A2171 | Carboplatin | 41575-94-4 | 99.50% | Antitumor agent that forms platinum-DNA adducts. |
| A2173 | SC 144 | 895158-95-9 | 99.21% | Gp130 inhibitor |
| A2174 | Lenvatinib (E7080) | 417716-92-8 | 99.11% | VEGFR inhibitor |
| A2187 | Cladribine | 4291-63-8 | 98.01% | Apoptosis inducer in CLL cells |
| A2198 | Genistein | 446-72-0 | 99.24% | ER agonist |
| A2213 | 17-DMAG (Alvespimycin) HCl | 467214-21-7 | 99.22% | Hsp90 inhibitor |
| A2224 | Stattic | 19983-44-9 | 99.82% | STAT3 inhibitor,small-molecule and potent |
| A2249 | T0901317 | 293754-55-9 | 99.91% | Liver X receptor agonist,potent and selective |
| A2251 | Tivozanib (AV-951) | 475108-18-0 | 98.26% | VEGFR inhibitor,potent and selective |
| A2278 | NVP-AEW541 | 475489-16-8 | 98.00% | IGF-IR inhibitor, novel, potent and selective |
| A2306 | Ellagic acid | 476-66-4 | 98.39% | Casein kinase 2 (CK2) inhibitor |
| A2307 | PHA-665752 | 477575-56-7 | 98.00% | C-Met inhibitor,potent and ATP-competitive |
| A2308 | TAK-438 | 1260141-27-2 | 98.00% | Blocker of potassium-competitive acid |
| A2310 | SR9009 | 1379686-30-2 | 99.71% | REV-ERB-α/β Agonist |
| A2323 | TCS 359 | 301305-73-7 | 99.26% | Potent FLT3 inhibitor |
| A2324 | Dexamethasone (DHAP) | 50-02-2 | 99.95% | Glucocorticoidan; anti-inflammatory |
| A2343 | Cyclophosphamide | 50-18-0 | 98.00% | Nitrogen mustard alkylating agent and prodrug. |
| A2355 | Mercaptopurine (6-MP) | 50-44-2 | 99.72% | Purine synthesis inhibitor |
| A2402 | Floxuridine | 50-91-9 | 99.22% | Antineoplastic antimetabolite |
| A2415 | Acitretin | 55079-83-9 | 99.87% | Metabolite of etretinate |
| A2431 | Acarbose | 56180-94-0 | 98.00% | Alpha-glucosidase inhibitor |
| A2436 | Fluoxetine HCl | 56296-78-7 | 99.60% | Serotonin reuptake inhibitor,selective |
| A2451 | Epirubicin HCl | 56390-09-1 | 98.62% | Antibiotic antitumor agent |
| A2456 | Pamidronate Disodium | 57248-88-1 | 98.00% | Bisphosphonate antiresorptive agent & bone resorption inhibitor |
| A2477 | Tyrphostin AG 1296 | 146535-11-7 | 99.90% | PDGFR inhibitor,selective and ATP-competitive |
| A2486 | Malotilate | 59937-28-9 | 98.72% | Stimulates hepatocyte regeneration |
| A2487 | Odanacatib (MK-0822) | 603139-19-1 | 99.04% | Cathepsin K,potent and selective |
| A2489 | Leucovorin Calcium | 6035-45-6 | 98.00% | Derivative of folic acid |
| A2510 | Ampicillin sodium | 69-52-3 | 98.00% | β-lactam antibiotic |
| A2511 | Carbenicillin, Disodium Salt | 4800-94-6 | 98.00% | Inhibits the cell-wall synthesis,antibiotic |
| A2512 | Chloramphenicol | 56-75-7 | 99.52% | Inhibits translation(blocking peptidyl transferase) |
| A2513 | Geneticin, G-418 Sulfate | 108321-42-2 | 98.00% | Aminoglycosidic antibiotic |
| A2515 | Hygromycin B | 31282-04-9 | 98.00% | Suitable for mammalian cell selection |
| A2516 | Kanamycin Sulfate | 25389-94-0 | 98.00% | Water-soluble antibiotic |
| A2517 | Tetracycline Hydrochloride | 64-75-5 | 98.48% | Bacteriostatic antibiotics |
| A2521 | VE-821 | 1232410-49-9 | 98.03% | ATR kinase inhibitor |
| A2531 | Fluoroorotic Acid, Ultra Pure | 703-95-7 | 99.62% | 5-Fluoroorotic acid |
| A2539 | X-Gal | 7240-90-6 | 99.48% | Substrate for β-galactosidase,used in blue/white screening |
| A2548 | Carmofur | 61422-45-5 | 98.00% | Cytostatic derivative of fluorouracilm,antineoplatic agent |
| A2552 | Quercetin dihydrate | 6151-25-3 | 98.23% | PLA2 and PI 3-kinase inhibitor |
| A2559 | Altretamine | 645-05-6 | 99.13% | Antineoplastic agent |
| A2570 | Leupeptin, Microbial | 103476-89-7 | 98.00% | Inhibitor of serine and cysteine proteases |
| A2571 | Pepstatin A | 26305-03-3 | 98.96% | Aspartic proteinases inhibitor |
| A2573 | AEBSF.HCl | 30827-99-7 | 99.68% | Serine protease inhibitor |
| A2574 | Aprotinin | 9087-70-1 | 98.00% | Inhibitor of bovine pancreatic trypsin |
| A2575 | Bestatin | 58970-76-6 | 98.00% | Aminopeptidase inhibitor |
| A2576 | E-64 | 66701-25-5 | 98.00% | Cysteine protease inhibitor,irriversible |
| A2577 | Batimastat (BB-94) | 130370-60-4 | 98.32% | MMP inhibitor |
| A2578 | Clasto-Lactacystin β-lactone | 154226-60-5 | ≥95.00% | Proteasome inhibitor |
| A2580 | Elastase Inhibitor, SPCK | 65144-34-5 | 98.00% | HLE inhibitor |
| A2583 | Lactacystin (Synthetic) | 133343-34-7 | 98.00% | Proteasome inhibitor |
| A2585 | MG-132 | 133407-82-6 | 97.56% | Proteasome inhibitor, Cell permeable, reversible |
| A2586 | Nafamostat Mesylate(FUT-175) | 82956-11-4 | 99.79% | Serine protease inhibitor |
| A2587 | PMSF | 329-98-6 | 99.78% | Serine proteinases inhibitor, irreversible |
| A2588 | PPACK Dihydrochloride | 142036-63-3 | 99.10% | Thrombin inhibitor |
| A2597 | Brivanib (BMS-540215) | 649735-46-6 | 99.59% | VEGFR-2 inhibitor,ATP-competitive |
| A2600 | (-)-Epigallocatechin gallate (EGCG) | 989-51-5 | 99.12% | Antioxidant, antiangiogenic and antitumor agent |
| A2601 | Aclacinomycin A | 57576-44-0 | 98.00% | Topoisomerase I and II inhibitor |
| A2602 | Calpain Inhibitor I, ALLN | 110044-82-1 | 98.00% | Calpain I/II/ B/L inhibitor |
| A2603 | Calpain Inhibitor II, ALLM | 136632-32-1 | 98.00% | Calpain inhibitor |
| A2604 | Celastrol | 34157-83-0 | 98.67% | Antioxidant, anti-inflammatory and immunosuppressive agent |
| A2606 | Epoxomicin | 134381-21-8 | 97.92% | Proteasome inhibitor |
| A2610 | Fenbendazole | 43210-67-9 | 99.57% | For pinworm treatment in animals |
| A2612 | MG-115 | 133407-86-0 | 98.00% | Potent reversible proteasome inhibitor |
| A2614 | Bortezomib (PS-341) | 179324-69-7 | 99.89% | Proteasome Inhibitor |
| A2623 | VU 0364439 | 1246086-78-1 | 98.00% | Positive allosteric mGluR-4 modulator |
| A2633 | Brivanib Alaninate (BMS-582664) | 649735-63-7 | 98.00% | VEGFR2 inhibitor,ATP-competitive |
| A2664 | VX-661 | 1152311-62-0 | 99.88% | F508del CFTR corrector |
| A2673 | AG-1024 | 65678-07-1 | 98.00% | Selective IGF-1R inhibitor |
| A2678 | SU11274 | 658084-23-2 | ≥95.00% | C-Met inhibitor,potent and selective |
| A2681 | TGX-221 | 663619-89-4 | 98.91% | PI3Kβ inhibitor,potent,selective and ATP competitive |
| A2689 | Butein | 487-52-5 | 98.00% | Protein kinase inhibitor |
| A2700 | 10Panx | 955091-53-9 | 99.29% | Panx-1 mimetic inhibitor |
| A2701 | Scrambled 10Panx | 1315378-72-3 | 98.68% | Panx-1 mimetic inhibitory peptide, blocks pannexin-1 gap junctions |
| A2754 | TG100-115 | 677297-51-7 | 98.02% | PI3Kγ/PI3Kδ inhibitor |
| A2782 | Amonafide | 69408-81-7 | 98.00% | DNA intercalator,Topo II inhibitor |
| A2806 | BX-912 | 702674-56-4 | 95.55% | PDK1 inhibitor,potent and ATP-competitive |
| A2813 | Ivermectin | 70288-86-7 | 98.00% | NAChR/purinergic P2X4 receptor modulator |
| A2822 | AC480 (BMS-599626) | 714971-09-2 | 98.00% | HER1/2 inhibitor,selective and efficacious |
| A2838 | OSI-930 | 728033-96-3 | 99.58% | Inhibitor of Kit, KDR, Flt, CSF-1R, c-Raf and Lck |
| A2842 | Melatonin | 73-31-4 | 99.81% | Melatonin receptors agonist |
| A2845 | Omeprazole | 73590-58-6 | 97.37% | H+,K+-ATPase inhibitor |
| A2846 | OSU-03012 (AR-12) | 742112-33-0 | 99.43% | Potent PDK1 inhibitor |
| A2852 | Leflunomide | 75706-12-6 | 99.69% | AHR agonist,immunosuppressive agent |
| A2884 | Doxazosin Mesylate | 77883-43-3 | 99.82% | α1-adrenergic receptor antagonist |
| A2890 | Nepafenac | 78281-72-8 | 98.00% | COX-1 and COX-2 inhibitor |
| A2917 | Flumazenil | 78755-81-4 | 99.85% | Benzodiazepine antagonist |
| A2942 | Masitinib (AB1010) | 790299-79-5 | 99.60% | Tyrosine kinase inhibitor, potent and selective |
| A2949 | Linifanib (ABT-869) | 796967-16-3 | 99.62% | VEGFR/PDGFR inhibitor |
| A2960 | Loratadine | 79794-75-5 | 98.24% | Peripheral HH1R antagonist |
| A2974 | Foretinib (GSK1363089) | 849217-64-7 | 98.36% | VEGF and HGF receptor inhibitor |
| A2977 | Cabozantinib (XL184, BMS-907351) | 849217-68-1 | 98.60% | VEGFR2/Met/Ret/Kit/FLT//AXL inhibitor |
| A2986 | ADL5859 HCl | 850173-95-4 | 99.16% | δ-opioid receptor agonist,selective |
| A3001 | PCI-32765 (Ibrutinib) | 936563-96-1 | 99.39% | Bruton’s tyrosine kinase (BTK) inhibitor |
| A3002 | ABT-888 (Veliparib) | 912444-00-9 | 99.87% | Potent PARP inhibitor |
| A3003 | MDV3100 (Enzalutamide) | 915087-33-1 | 99.78% | Androgen receptor antagonist |
| A3004 | Vemurafenib (PLX4032, RG7204) | 918504-65-1 | 98.48% | BRAF kinase inhibitor |
| A3005 | CAL-101 (Idelalisib, GS-1101) | 870281-82-6 | 99.91% | PI3K inhibitor |
| A3006 | GDC-0068 (RG7440) | 1001264-89-6 | 99.06% | Pan-AKT inhibitor,highly selective |
| A3007 | ABT-263 (Navitoclax) | 923564-51-6 | 98.02% | Potent Bcl-2 family inhibitor, inhibits Bcl-2, Bcl-xL, and Bcl-w |
| A3008 | Y-27632 dihydrochloride | 146986-50-7;129830-38-2 | 99.08% | ROCK1 inhibitor |
| A3009 | Sorafenib | 284461-73-0 | 99.87% | Raf kinases and tyrosine kinases inhibitor |
| A3010 | MK-2206 dihydrochloride | 1032350-13-2 | 99.59% | Akt1/2/3 inhibitor |
| A3011 | CHIR-99021 (CT99021) | 252917-06-9 | 98.32% | GSK-3 inhibitor, Cell-permeable, ATP-competitive |
| A3012 | Ruxolitinib (INCB018424) | 941678-49-5 | 99.64% | JAK inhibitor |
| A3013 | PD0325901 | 391210-10-9 | 99.74% | MEK inhibitor |
| A3014 | BGJ398 | 872511-34-7 | 99.74% | FGFR inhibitor ,potent and selective |
| A3015 | BKM120 | 944396-07-0 | 98.01% | Inhibitor of pan-Class I PI3K |
| A3016 | PLX-4720 | 918505-84-7 | 98.70% | BRAF kinase inhibitor |
| A3017 | Dasatinib (BMS-354825) | 302962-49-8 | 98.09% | Src and BCR-Abl inhibitor |
| A3018 | Trametinib (GSK1120212) | 871700-17-3 | 98.98% | MEK1 and MEK2 inhibitor, potent and selective |
| A3019 | AT-406 (SM-406) | 1071992-99-8 | 98.00% | IAP inhibitor |
| A3021 | GDC-0449 (Vismodegib) | 879085-55-9 | 99.64% | Hedgehog antagonist,potent and selective |
| A3022 | Pazopanib (GW-786034) | 444731-52-6 | 98.81% | VEGFR/PDGFR/FGFR inhibitor |
| A3023 | P005091 | 882257-11-6 | 99.67% | Ubiquitin-specific protease 7 (USP7) inhibitor |
| A3100 | (+)-MK 801 | 70449-94-4 | 99.38% | Potent NMDA antagonist |
| A3104 | (E)-2-Decenoic acid | 334-49-6 | 98.00% | Fatty acid identified in royal jelly |
| A3108 | 17 alpha-propionate | 19608-29-8 | 98.00% | Androgen antagonist |
| A3111 | 1alpha, 25-Dihydroxy VD2-D6 | 216244-04-1 | 98.00% | Deuterated form of vitamin D |
| A3115 | 24, 25-Dihydroxy VD3 | 40013-87-4 | 98.00% | Vitamin D analogue |
| A3118 | 3,3′-Diindolylmethane | 1968-05-4 | 99.69% | Anticancer and antineoplastic agent |
| A3119 | 360A | 794458-56-3 | 98.00% | G-quadruplex structures inhibitor |
| A3120 | 360A iodide | 737763-37-0 | 98.56% | G-quadruplex structures inhibitor |
| A3122 | PI4KIII beta inhibitor 3 | 1245319-54-3 | 98.00% | PI4KIII beta inhibitor |
| A3123 | 4′-Demethylepipodophyllotoxin | 6559-91-7 | 99.32% | Anti-cancer drug |
| A3124 | 5-hydroxypyrazine-2-carboxylic acid | 34604-60-9 | 99.15% | Metabolite of pyrazinamide (PZA) |
| A3125 | 5-Iodotubercidin | 24386-93-4 | 98.34% | Adenosine kinase inhibitor,potent |
| A3126 | 5-R-Rivaroxaban | 865479-71-6 | 99.49% | Factor Xa (FXa) inhibitor |
| A3130 | A 438079 | 899507-36-9 | 98.00% | P2X7 receptor antagonist,competitive and selective |
| A3131 | A 438079 hydrochloride | 899431-18-6 | 99.59% | P2X7 receptor antagonist,competitive and selective |
| A3132 | A 77-01 | 607737-87-1 | 99.50% | Potent ALK5 inhibitor |
| A3133 | A 83-01 | 909910-43-6 | 99.24% | ALK-5 inhibitor |
| A3134 | A-317491 | 475205-49-3 | 98.53% | P2X3 and P2X2/3 receptor antagonist |
| A3135 | A-443654 | 552325-16-3 | 99.79% | Akt inhibitor,potent and selective |
| A3136 | A-740003 | 861393-28-4 | 98.24% | P2X7 receptor antagonist |
| A3138 | A-867744 | 1000279-69-5 | 98.00% | Allosteric Modulator |
| A3139 | Abacavir | 136470-78-5 | 99.89% | Inhibitor of HIV reverse transcriptase |
| A3142 | Acamprosate calcium | 77337-73-6 | 99.78% | GABA receptor agonist and modulator of glutamatergic systems |
| A3143 | Adarotene | 496868-77-0 | 99.24% | Apoptosis inducer/DNA damage agent |
| A3145 | Afatinib dimaleate | 850140-73-7 | 99.49% | EGFR inhibitor |
| A3146 | AGI-6780 | 1432660-47-3 | 98.63% | IDH2/R140Q mutation inhibitor |
| A3147 | AH 6809 | 33458-93-4 | 98.00% | EP and DP receptor antagonist |
| A3148 | AIM-100 | 873305-35-2 | 98.95% | Ack1 inhibitor |
| A3149 | AKT inhibitor VIII | 612847-09-3 | 99.73% | Allosteric Akt kinase inhibitor |
| A3151 | Alarelin Acetate | 79561-22-1 | 99.88% | Synthetic GnRH agonist |
| A3153 | Aliskiren | 173334-57-1 | 98.95% | Direct renin inhibitor |
| A3155 | ALK inhibitor 2 | 761438-38-4 | 98.00% | ALK inhibitor, novel and selective |
| A3156 | Alogliptin Benzoate | 850649-62-6 | 98.00% | DPP-4 inhibitor,selective and potent,antidiabetic drug |
| A3157 | Alosetron | 122852-42-0 | 98.00% | 5-HT3 receptor antagonist |
| A3159 | Alosetron Hydrochloride | 122852-69-1 | 98.91% | 5-HT3 receptor antagonist,potent and highly selective |
| A3162 | Alvimopan | 156053-89-3 | 99.67% | Mu-opioid receptors antagonist |
| A3163 | Alvimopan dihydrate | 170098-38-1 | 98.00% | μ-opioid receptor antagonist,peripherally acting |
| A3165 | ALW-II-41-27 | 1186206-79-0 | 97.45% | Eph receptor inhibitor |
| A3166 | AM095 | 1345614-59-6 | 98.14% | Potent LPA1 receptor antagonist |
| A3167 | AM-095 free base | 1228690-36-5 | 98.12% | Potent LPA1 receptor antagonist |
| A3169 | AM679 | 1206880-66-1 | 98.00% | FLAP inhibitor |
| A3170 | AM966 | 1228690-19-4 | 99.69% | LPA1 antagonist, oral active, high affinity, selective, |
| A3171 | Amadacycline | 389139-89-3 | 99.46% | Tetracycline antibiotic |
| A3173 | AMD-070 | 558447-26-0 | 98.00% | CXCR4 antagonist,potent and selective |
| A3174 | AMD-070 hydrochloride | 880549-30-4 | 98.00% | CXCR4 antagonist,potent and selective |
| A3176 | Ampalex | 154235-83-3 | 98.54% | Ampakine and nootropic |
| A3177 | AN-2690 | 174671-46-6 | 98.60% | Antifungal agent |
| A3178 | AN-2728 | 906673-24-3 | 99.33% | PDE4 inhibitor,anti-inflammatory compound |
| A3179 | Anamorelin | 249921-19-5 | 99.68% | Ghrelin receptor agonist, synthetic, orally active |
| A3182 | Anguizole | 442666-98-0 | 98.00% | Inhibitor of HCV replication |
| A3184 | AR-A014418 | 487021-52-3 | 98.34% | GSK3β inhibitor, ATP-competitive and selective |
| A3185 | AR-C155858 | 496791-37-8 | 99.52% | MCT1 and MCT2 inhibitor |
| A3188 | ARRY-520 R enantiomer | 885060-08-2 | 98.00% | KSP inhibitor |
| A3189 | AS 602801 | 848344-36-5 | 98.72% | Jun Kinase Inhibitor |
| A3190 | ASC-J9 | 52328-98-0 | 98.00% | AR degradation enhancer,antiumor agent |
| A3191 | Ascomycin(FK 520) | 104987-12-4 | 98.00% | Macrolide immunosuppressant,FK-520 analog |
| A3192 | Asenapine hydrochloride | 1412458-61-7 | 98.00% | Atypical antipsychotic |
| A3193 | ASP3026 | 1097917-15-1 | 99.38% | ALK inhibitor,potent and selective |
| A3194 | AST 487 | 630124-46-8 | 99.29% | RET kinase inhibitor |
| A3195 | Asunaprevir (BMS-650032) | 630420-16-5 | 99.80% | NS3 protease inhibitor |
| A3196 | AT-101 | 90141-22-3 | 98.00% | BH3-mimetic,gossypol enantiomer |
| A3197 | AT7519 Hydrochloride | 902135-91-5 | 99.80% | Multi-CDK inhibitor |
| A3198 | AT7519 trifluoroacetate | 1431697-85-6 | 98.00% | CDK/cyclin inhibitor |
| A3199 | AT7867 dihydrochloride | 1431697-86-7 | 98.00% | Akt1 and p70S6K/PKA inhibitor |
| A3201 | Atrasentan hydrochloride | 195733-43-8 | 98.00% | Endothelin receptor antagonist |
| A3202 | Avermectin B1 | 71751-41-2 | 98.00% | Insecticide |
| A3206 | AVL-292 | 1202757-89-8 | 98.27% | Btk inhibitor |
| A3208 | Avosentan | 290815-26-8 | 98.00% | ETA receptor antagonist |
| A3209 | AXL1717 | 477-47-4 | 98.07% | IGF-1R inhibitor,orally active |
| A3210 | AZ20 | 1233339-22-4 | 99.93% | ATR inhibitor,potent and selective |
| A3214 | AZD1152 | 722543-31-9 | 98.78% | Aurora B kinase inhibitor,highly potent and selective |
| A3215 | AZD7687 | 1166827-44-6 | 98.00% | DGAT inhibitor,potent and selective |
| A3216 | Balaglitazone | 199113-98-9 | 99.62% | PPAR-γ partial agonist |
| A3217 | Balapiravir | 690270-29-2 | 98.00% | Polymerase inhibitor,anti-HCV |
| A3218 | BAM7 | 331244-89-4 | 98.00% | BAX activator,direct and selective |
| A3219 | BAN ORL 24 | 475150-69-7 | 98.00% | NOP receptor antagonist, potent and selective |
| A3220 | Bardoxolone | 218600-44-3 | 99.55% | Once-a-day treatment for CKD |
| A3221 | Bardoxolone methyl | 218600-53-4 | 98.75% | IKK inhibitor, potent antioxidant inflammation modulator |
| A3222 | Baricitinib phosphate | 1187595-84-1 | 99.59% | JAK1/JAK2 inhibitor |
| A3227 | BAY 61-3606 | 732983-37-8 | 98.45% | Syk Inhibitor |
| A3228 | BAY 61-3606 dihydrochloride | 648903-57-5 | 98.00% | Syk tyrosine kinase inhibitor |
| A3230 | Bay 65-1942 HCl salt | 600734-06-3 | 98.00% | IKKβ kinase inhibitor |
| A3232 | Bazedoxifene | 198481-32-2 | 98.00% | Estrogen receptor modulator |
| A3236 | Benfotiamine | 22457-89-2 | 99.76% | Drug for painful nerve condition |
| A3237 | Betulinic acid | 472-15-1 | 98.00% | Anti-HIV and antitumor compound,pentacyclic triterpenoid |
| A3238 | BEZ235 Tosylate | 1028385-32-1 | 98.28% | MTOR/P13K inhibitor |
| A3239 | B-HT 920 | 36085-73-1 | 98.00% | D2 receptor agonist |
| A3240 | BIBX 1382 | 196612-93-8 | 98.00% | EGFR inhibitor,potent and selective |
| A3241 | Bilobalide | 33570-04-6 | 98.00% | Neuroprotective agent |
| A3242 | Bitopertin | 845614-11-1 | 99.70% | Glycine reuptake inhibitor(GlyT1) |
| A3244 | Bivalirudin Trifluoroacetate | 128270-60-0 | 98.07% | Reversible thrombin inhibitor |
| A3246 | BMN-673 8R,9S | 1207456-00-5 | 99.75% | Inactive form of BMN 673, used as negative control |
| A3248 | BMS345541 hydrochloride | 547757-23-3 | 99.57% | IKK inhibitor,highly selective |
| A3250 | BMS-509744 | 439575-02-7 | 98.00% | Itk inhibitor,potent and selective |
| A3252 | BMS-599626 Hydrochloride | 873837-23-1 | 99.58% | EGFR/HER2 inhibitor,potent and selective |
| A3253 | BMS-626529 | 701213-36-7 | 98.01% | HIV-1 attachment inhibitor |
| A3254 | BMS-663068 | 864953-29-7 | 98.00% | HIV-1 attachment inhibitor |
| A3256 | BMS-690514 | 859853-30-8 | 98.00% | HER/EGFR inhibitor |
| A3257 | BMS-790052 dihydrochloride | 1009119-65-6 | 99.81% | HCV NS5A inhibitor |
| A3258 | BMS-833923 | 1059734-66-5 | 99.84% | Smoothened inhibitor |
| A3259 | BMS-927711 | 1289023-67-1 | 98.99% | CGRP receptor antagonist |
| A3260 | BMX-IN-1 | 1431525-23-3 | 97.99% | BMX (also termed ETK) kinase inhibitor |
| A3261 | Boceprevir | 394730-60-0 | 98.00% | HCV protease inhibitor,potent and selective |
| A3263 | BRAF inhibitor | 918505-61-0 | 98.00% | Potent B-raf inhibitor |
| A3264 | B-Raf inhibitor | 1315330-11-0 | 98.00% | A B-Raf inhibitor |
| A3265 | Brassinolide | 72962-43-7 | 98.00% | Plant growth regulator |
| A3266 | BS-181 | 1092443-52-1 | 98.00% | CDK7 inhibitor,highly selective |
| A3268 | CAL-130 Hydrochloride | 1431697-78-7 | 98.00% | PI3K inhibitor |
| A3270 | Calcifediol monohydrate | 63283-36-3 | 99.43% | Prehormone;vitamin D3 metabolite |
| A3271 | Calcipotriol | 112965-21-6 | 98.00% | Vitamin D3 analog,regulates cell differentiation and proliferation |
| A3275 | Calcium-Sensing Receptor Antagonists I | 478963-79-0 | 98.00% | CaSR antagonist |
| A3276 | Canertinib dihydrochloride | 289499-45-2 | 99.72% | Pan-ErbB inhibitor, potent and selective |
| A3277 | Capadenoson | 544417-40-5 | 98.00% | Adenosine A1 receptor agonist |
| A3278 | Nonivamide (Capsaicin Analog) | 2444-46-4 | 99.53% | TRPV1 receptor agonist |
| A3279 | Capsazepine | 138977-28-3 | 99.25% | TRPV1 ion channel antagonist |
| A3282 | Cariprazine | 839712-12-8 | 99.19% | D2/D3 partial agonist,antipsychotic drug |
| A3284 | Cathepsin S inhibitor | 1373215-15-6 | 98.33% | Blocks MHCII antigen presentation |
| A3285 | CB 300919 | 289715-28-2 | 98.00% | Potential therapy for ovarian cancer |
| A3286 | CB30865 | 206275-15-2 | 98.00% | Nampt inhibitor |
| A3287 | CC-401 hydrochloride | 1438391-30-0 | 98.00% | JNK inhibitor |
| A3288 | CC-930 | 899805-25-5 | 98.00% | JNK inhibitor,potent and selective |
| A3289 | CCG-63802 | 620112-78-9 | 98.00% | RGS protein inhibitor |
| A3290 | CCG-63808 | 620113-73-7 | 98.00% | Reversible RGS inhibitor |
| A3291 | CCT241533 | 1262849-73-9 | 98.00% | Potent Chk2 inhibitor |
| A3292 | CCT241533 hydrochloride | 1431697-96-9 | 98.00% | CHK2 kinase inhibitor, novel |
| A3293 | CDK inhibitor II | 1269815-17-9 | 98.00% | CDK inhibitor |
| A3294 | CDK9 inhibitor | 1415559-43-1 | 98.00% | CDK9 inhibitor |
| A3295 | CDK9 inhibitor 2 | 1263369-28-3 | 98.00% | CDK9 inhibitor |
| A3297 | CEP-32496 hydrochloride | 1227678-26-3 | 98.00% | B-Raf/C-Raf inhibitor,highly potent |
| A3297 | CEP-32496 hydrochloride | 1227678-26-3 | 98.00% | B-Raf/C-Raf inhibitor,highly potent |
| A3298 | Cetirizine | 83881-51-0 | 99.65% | Antihistamine |
| A3300 | Cevimeline hydrochloride hemihydrate | 153504-70-2 | 98.00% | Agonist of muscarinic receptor (M1/M3) |
| A3302 | CGI-1746 | 910232-84-7 | 98.00% | Btk inhibitor |
| A3303 | CGP60474 | 164658-13-3 | 98.00% | CDKs and PKC inhibitor, potent |
| A3304 | CGS 21680 | 120225-54-9 | 98.00% | Adenosine A2 receptor agonists,potent and selective |
| A3305 | CHAPS | 75621-03-3 | 97.71% | Zwitterionic detergent for membrane proteins,nondenaturing |
| A3306 | Chelerythrine Chloride | 3895-92-9 | 99.36% | PKC antagonist |
| A3307 | CHIR-090 | 728865-23-4 | 99.37% | Potent LpxC inhibitor |
| A3308 | Choline Fenofibrate | 856676-23-8 | 99.92% | Choline salt of fenofibric acid |
| A3309 | CHR-6494 | 1333377-65-3 | 98.00% | Haspin inhibitor,potent ands selective |
| A3310 | chroman 1 | 1273579-40-0 | 98.00% | ROCK II inhibitor, highly potent and selective |
| A3311 | CID-2858522 | 758679-97-9 | 98.00% | NF-κB pathway inhibitor |
| A3313 | Cinacalcet | 226256-56-0 | 99.48% | Calcimimetic agent,orally active |
| A3314 | Cinaciguat | 329773-35-5 | 98.00% | Soluble guanylate cyclase (sGC) activators |
| A3315 | Clemizole | 442-52-4 | 99.06% | H1 histamine receptor antagonist |
| A3316 | Clemizole hydrochloride | 1163-36-6 | 99.73% | H1 histamine receptor antagonist |
| A3317 | Clozapine N-oxide (CNO) | 34233-69-7 | 99.74% | Metabolite of clozapine, used in chemogenetics. |
| A3319 | CMK | 821794-90-5 | 98.00% | RSK2 kinase inhibitor |
| A3320 | CO-1686 (AVL-301) | 1374640-70-6 | 99.28% | EGFR inhibitor |
| A3321 | Cobimetinib | 934660-93-2 | 99.71% | Selective MEK inhibitor |
| A3322 | Cobimetinib (racemate) | 934662-91-6 | 98.00% | Selective MEK inhibitor |
| A3331 | CP-809101 hydrochloride | 1215721-40-6 | 98.00% | 5-HT2C receptor agonist, potent and selective |
| A3334 | CTS-1027 | 193022-04-7 | 98.00% | MMPs inhibitor |
| A3335 | Curcumin | 458-37-7 | 98.36% | Tyrosinase inhibitor |
| A3336 | CVT-313 | 199986-75-9 | 98.04% | Cdk2 inhibitor |
| A3337 | CX-6258 | 1202916-90-2 | 98.28% | Pan-Pim kinases Inhibitor |
| A3339 | CYT387 sulfate salt | 1056636-06-6 | 98.00% | JAK1/JAK2 inhibitor |
| A3340 | CZC24832 | 1159824-67-5 | 98.00% | Selective PI3K-γ inhibitor |
| A3342 | D4476 | 301836-43-1 | 99.22% | CK1/ALK5 inhibitor,specific and cell permeable |
| A3343 | D609 | 83373-60-8 | 98.00% | PC-PLC inhibitor |
| A3344 | D-64131 | 74588-78-6 | 98.00% | Tubulin polymerization inhibitor |
| A3345 | Dabigatran etexilate mesylate | 872728-81-9 | 99.41% | Direct thrombin inhibitor,anticoagulant,prodrug of dabigatran |
| A3346 | Dabigatran ethyl ester | 429658-95-7 | 98.00% | Thrombin activity inhibitor |
| A3347 | Dabrafenib Mesylate (GSK-2118436) | 1195768-06-9 | 99.78% | Inhibitor of BRAF(V600) mutants |
| A3348 | Daminozide | 1596-84-5 | 98.00% | KDM2A inhibitor |
| A3349 | Darapladib | 356057-34-6 | 99.54% | Lp-PLA2 inhibitor, selective and orally active |
| A3351 | Dasatinib hydrochloride | 854001-07-3 | 99.91% | Multi-BCR/Abl and Src kinase inhibitor, oral active |
| A3352 | Daun02 | 290304-24-4 | 98.00% | Cell viability inhibitor,DNA synthisis inhibitor |
| A3353 | DB07268 | 929007-72-7 | 98.84% | JNK1 inhibitor |
| A3355 | Deferasirox Fe3+ chelate | 554435-83-5 | 98.00% | Oral iron chelator |
| A3356 | Delafloxacin | 189279-58-1 | 99.81% | Fluoroquinolone antibiotic |
| A3357 | Delafloxacin meglumine | 352458-37-8 | 98.00% | Fluoroquinolone antibiotic agent |
| A3358 | Deltarasin | 1440898-61-2 | 98.00% | KRAS-PDEδ interaction inhibitor |
| A3359 | Desmopressin | 16679-58-6 | 98.66% | Hemostatic and anti-diuretic |
| A3360 | Desmopressin Acetate | 62288-83-9 | 98.73% | Synthetic analogue of arginine vasopressin |
| A3363 | DGAT-1 inhibitor | 701232-20-4 | 99.64% | Diacylglycerol acyltransferase (DGAT1) inhibitor |
| A3366 | Dipraglurant | 872363-17-2 | 98.00% | mGluR5 antagonist |
| A3368 | DMAT | 749234-11-5 | 98.60% | CK2 inhibitor,potent and selective |
| A3369 | DMP 777 | 157341-41-8 | 98.00% | Leukocyte elastase (HLE) inhibitor |
| A3370 | Docetaxel Trihydrate | 148408-66-6 | 99.78% | Depolymerisation of microtubules inhibitor |
| A3371 | Doramectin | 117704-25-3 | 97.08% | Antiparasitic antibiotic |
| A3374 | Dronedarone | 141626-36-0 | 99.58% | CYP3A4 and 2D6 inhibitor,moderate |
| A3375 | DY131 | 95167-41-2 | 99.82% | ERRγ agonist |
| A3378 | E-3810 | 1058137-23-7 | 98.00% | VEGF/FGF dual inhibitor, potent and selective |
| A3380 | Ebrotidine | 100981-43-9 | 98.00% | H2-receptor antagonist,competitive |
| A3381 | Edoxaban | 480449-70-5 | 99.27% | Factor Xa inhibitor |
| A3383 | Edoxaban tosylate monohydrate | 1229194-11-9 | 99.34% | Oral factor Xa inhibitor |
| A3384 | Elacridar | 143664-11-3 | 98.17% | BCRP inhibitor |
| A3385 | Elacridar hydrochloride | 143851-98-3 | 98.00% | BCRP and P-GP inhibitor |
| A3387 | Eltrombopag Olamine | 496775-62-3 | 98.49% | C-mpl agonist |
| A3389 | EMD638683 | 1181770-72-8 | 98.46% | SGK1 inhibitor |
| A3392 | Emodin | 518-82-1 | 99.09% | Naturally occurring anthraquinone,antiproliferative |
| A3394 | Epothilone D | 189453-10-9 | 98.00% | Natural polyketide compound |
| A3395 | Ercalcidiol | 21343-40-8 | 98.00% | Vitamin D2 metabolite,ligand of VDR-like receptors |
| A3396 | Ercalcitriol | 60133-18-8 | 98.00% | Active metabolite of vitamin D2 |
| A3397 | Erlotinib | 183321-74-6 | 99.47% | EGFR tyrosine kinase inhibitor |
| A3399 | Esomeprazole Magnesium trihydrate | 217087-09-7 | 98.32% | Proton pump inhibitor |
| A3401 | Etifoxine hydrochloride | 56776-32-0 | 99.87% | GABAA receptor potentiator |
| A3403 | Etofenamate | 30544-47-9 | 98.05% | Non-steroidal anti-inflammatory drug |
| A3404 | Etomoxir | 124083-20-1 | 99.75% | (CPT)-1 and DGAT activity inhibitor |
| A3405 | Etoricoxib | 202409-33-4 | 99.82% | Specific COX-2 inhibitor |
| A3407 | EVP-6124 hydrochloride | 550999-74-1 | 99.85% | Alpha7 nAChR agonist |
| A3408 | Exendin-4 | 141758-74-9 | 99.66% | GLP-1 activator |
| A3411 | Faropenem daloxate | 141702-36-5 | 98.00% | Oral penem,beta-lactam antibiotic |
| A3412 | Fenretinide | 65646-68-6 | 98.00% | Synthetic retinoid agonist |
| A3413 | FH535 | 108409-83-2 | 99.62% | Wnt/B-catenin inhibitor |
| A3415 | Firategrast | 402567-16-2 | 99.56% | α4β1/α4β7 integrin antagonist |
| A3416 | FK 3311 | 116686-15-8 | 98.00% | Selective COX-2 inhibitor |
| A3417 | Flavopiridol | 146426-40-6 | 99.52% | Pan-cdk inhibitor |
| A3418 | Flecainide acetate | 54143-56-5 | 99.82% | Antiarrhythmic drug |
| A3419 | Fluvastatin | 93957-54-1 | 98.33% | HMGCR inhibitor |
| A3420 | FMK | 821794-92-7 | 98.82% | RSK inhibitor |
| A3421 | Fosamprenavir Calcium Salt | 226700-81-8 | 99.71% | Prodrug of antiretroviral protease inhibitor amprenavir |
| A3423 | Galanthamine | 357-70-0 | 99.12% | Acetylcholinesterase inhibitor |
| A3424 | Gambogic Acid | 2752-65-0 | 98.54% | Caspase activator and apoptosis inducer |
| A3429 | GANT 58 | 64048-12-0 | 99.38% | GLI antagonist,novel and potent |
| A3432 | GDC-0941 dimethanesulfonate | 957054-33-0 | 99.78% | PI3K inhibitor |
| A3433 | Gefitinib hydrochloride | 184475-55-6 | 99.87% | Potent EGFR inhibitor |
| A3434 | Genz-644282 | 529488-28-6 | 98.00% | Non-camptothecin inhibitor of topoisomerase I |
| A3435 | glucagon receptor antagonists 1 | 503559-84-0 | 98.00% | Glucagon receptor antagonist,highly potent |
| A3436 | glucagon receptor antagonists 2 | 202917-18-8 | 98.00% | Glucagon receptor antagonist,highly potent |
| A3437 | glucagon receptor antagonists 3 | 202917-17-7 | 98.00% | Glucagon receptor antagonist |
| A3438 | Glucocorticoid receptor agonist | 1245526-82-2 | 98.00% | Glucagon receptor antagonist |
| A3440 | Glyoxalase I inhibitor | 221174-33-0 | 98.00% | Glyoxalase I inhibitor |
| A3441 | GPR120 modulator 1 | 1050506-75-6 | 98.00% | GPR120 modulator |
| A3442 | GPR120 modulator 2 | 1050506-87-0 | 98.00% | GPR120 modulator |
| A3443 | Granisetron | 109889-09-0 | 98.00% | Serotonin 5-HT3 receptor antagonist |
| A3444 | GS-9620 | 1228585-88-3 | 98.01% | TLR-7 agonist |
| A3445 | GSK 525768A | 1260530-25-3 | 98.00% | inactive stereoisomer of I-BET-762 |
| A3446 | GSK126 | 1346574-57-9 | 98.32% | EZH2 inhibitor |
| A3448 | GSK2606414 | 1337531-36-8 | 98.18% | PERK inhibitor,potent and selective |
| A3449 | GSK343 | 1346704-33-3 | 98.95% | EZH2 inhibitor,potent,selective and cell permeable |
| A3450 | GSK-923295 | 1088965-37-0 | 98.28% | CENP-E inhibitor,small-molecule |
| A3451 | Guanfacine hydrochloride | 29110-48-3 | 99.41% | α2A-adrenoceptor agonist |
| A3452 | GW-1100 | 306974-70-9 | 98.00% | GPR40 antagonist |
| A3453 | GW1929 | 196808-24-9 | 98.00% | Potent PPARγ agonist |
| A3454 | GW3965 | 405911-09-3 | 98.00% | HLXRα/hLXRβ agonist,potent and selective |
| A3456 | GW843682X | 660868-91-7 | 98.00% | PLK1/PLK3 inhibitor,potent and selective |
| A3460 | HhAntag | 496794-70-8 | 98.95% | GLI1-mediated transcription inhibitor |
| A3461 | HIV-1 integrase inhibitor | 544467-07-4 | 98.00% | Uesful for anti-HIV |
| A3465 | HOE 33187 | 23623-08-7 | 98.00% | Blue fluorescent dyes |
| A3466 | Hoechst 33258 | 23491-45-4 | 99.88% | Blue fluorescent dyes |
| A3472 | Hoechst 33342 | 875756-97-1 | 98.84% | Blue fluorescent dyes |
| A3475 | Hoechst 34580 | 23555-00-2 | 97.70% | Blue fluorescent dyes |
| A3477 | HOKU-81 | 58020-43-2 | 98.00% | Bronchodilators,metabolite of tulobuterol |
| A3478 | Hydroxyfasudil | 105628-72-6 | 98.00% | Rho-kinase inhibitor and vasodilator |
| A3479 | Hydroxyfasudil hydrochloride | 155558-32-0 | 98.71% | Rho-kinase inhibitor and vasodilator |
| A3481 | Ibutamoren Mesylate | 159752-10-0 | 98.00% | Growth hormone (GH) secretagogue |
| A3482 | Icotinib Hydrochloride | 1204313-51-8 | 98.00% | EGFR inhibitor,potent and specific |
| A3483 | IDO inhibitor 1 | 1204669-37-3 | 99.83% | Indoleamine-2,3-dioxygenase inhibitor |
| A3484 | Iguratimod | 123663-49-0 | 98.00% | COX-2 inhibitor,inhibits IL-1,IL-6,IL-8 and tumour necrosis factor. |
| A3485 | IKK-2 inhibitor VIII | 406209-26-5 | 98.00% | IKK-2 inhibitor,potent and selective |
| A3486 | IKK-3 Inhibitor | 862812-98-4 | 98.00% | IKK-3 Inhibitor |
| A3487 | Imatinib hydrochloride | 862366-25-4 | 98.00% | V-Abl/c-Kit/PDGFR inhibitor |
| A3492 | INCB 3284 dimesylate | 887401-93-6 | 98.00% | HCCR2 antagonist |
| A3493 | INCB024360 analogue | 914471-09-3 | 99.81% | potent and selective inhibitor of IDO1 |
